Table 1.
Changes in urodynamic parameters induced by cyclophosphamide (CYP; 200 mg·kg−1, i.p.) and effect of the pretreatment with SB225002 (0.3 mg·kg−1, i.p.), SB366791 (0.3 mg·kg−1, i.p.) or SB225002 co-injected with SB366791 (0.3 mg·kg−1, i.p., each)
| Saline | CYP | SB225002 | SB366791 | SB225002 + SB366791 | |
|---|---|---|---|---|---|
| Number of NVCs | 3.6 ± 0.5 | 15.3 ± 0.5*2010 | 10.3 ± 0.4# | 11 ± 0.3# | 6 ± 0.3$ |
| Basal pressure (BP; mmHg) | 8.2 ± 0.3 | 18.5 ± 0.4*2010 | 11.8 ± 1.0# | 16.1 ± 1.1# | 7.2 ± 0.5$ |
| Threshold pressure (TP; mmHg) | 8.5 ± 0.9 | 19.1 ± 0.3*2010 | 12.7 ± 1.5# | 15.4 ± 1.1 | 7.4 ± 0.3$ |
| Maximum voiding pressure (MP; mmHg) | 11.3 ± 0.5 | 24.6 ± 0.3*2010 | 18.7 ± 0.4# | 17.3 ± 0.5# | 11.5 ± 0.3$ |
| Intercontraction interval (ICI; min) | 3.8 ± 0.1 | 1.2 ± 0.1*2010 | 2.3 ± 0.2# | 2.4 ± 0.2# | 3.3 ± 0.2$ |
| Voided volume (VV; mL) | 0.14 ± 0.01 | 0.037 ± 0.004*2010 | 0.074 ± 0.005# | 0.072 ± 0.006# | 0.11 ± 0.003$ |
| Bladder capacity (BC; mL) | 1.0s1 ± 0.06 | 0.5 ± 0.02*2010 | 0.76 ± 0.02# | 0.71 ± 0.03# | 0.88 ± 0.03$ |
| Voiding efficiency (%) | 75 ± 1.8 | 7.2 ± 1.5*2010 | 35 ± 4.8# | 31.6 ± 4.7# | 53.3 ± 2.1$ |
Values represent the mean ± SEM of six animals
*
P < 0.05, significantly different from control (saline) values.
#
P < 0.05, significantly different from cyclophosphamide values.
$
P < 0.05, significantly different from SB225002 or SB366791 values; one-way anova followed by Bonferroni's post hoc test.
NVCs, non-voiding contractions.